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 Prevalence of the disease in Belgium 
 Alpha-1 antitrypsin (AAT) deﬁ ciency is a hereditary recessive disorder. Up 
to now, more than 100 genetic variants have been recognized. Pi*M is the 
normal allele. 
 In Belgium, as in most countries, patients suﬀ ering from AAT severe 
deﬁ ciency are essentially Pi*ZZ homozygotes (in clinical practice, 96% of the 
related diseases are linked to this phenotype) and, to a lesser extent, some 
Pi*SZ heterozygotes. 
 International publications concerning the distribution of the gene fre-
quencies in Europe have mentioned only one speciﬁ c study in Belgium. 1 Th is 
only source concerned a neonatal screening in Limburg. 2 Th e AAT pheno-
type was determined in cord blood of 1345 Belgian newborns. Th e preva-
lence of the Pi*S and Pi*Z deﬁ ciency alleles were estimated to 54.3 and 16.7 
cases per 1000 inhabitants, respectively. Another Belgian study screened 
systematically for AAT deﬁ ciency in 39.289 consecutive births in Liège. Data 
suggested a prevalence of 3.6% and 1.4% of Pi*S and Pi*Z alleles (36 and 14 
cases for 1000 inhabitants, respectively). 3 
 In 2014, the population of Belgium is estimated to 11.203.992 inhabit-
ants. 4 Th erefore, taking the two Belgian studies into account, the number of 
Pi*ZZ patients in Belgium would be between 2196 and 2896. Th is ﬁ gure can 
seem high, compared with the number of estimated Pi*ZZ patients in Th e 
Ne therlands (frequency of PI*Z allele = 10 cases per 1000 inhabitants). Would 
the estimation of 1120 Pi*ZZ patients in Belgium not have been more realistic? 
 Belgian participation to the adult Alpha1-
International Registry (AIR) 
 During the WHO meeting on AAT deﬁ ciency in 1996, 5 the guidelines rec-
ommended the establishment of national and international registries of AAT 
deﬁ ciency, favoring collaborative research and development of adequately 
powered clinical trials. Th e Alpha-1 International Registry (AIR) was created 
 Abstract 
 A Belgian alpha-1-antitrypsin (AAT) deﬁ ciency registry has been established 
in 2003. Currently 55 patients are included. At the same time, a working group 
has been set up for publishing national guidelines. In 2014, several Belgian 
patients founded Alpha-1 Global. We hope that the integrated activities of all the 
stakeholders involved in AAT deﬁ ciency will permit a high quality care for all 
patients suffering from this disabling disease. 
* Jacques Hutsebaut, Wim Janssens, Renaud Louis 
and Eric Derom participated on behalf of the 
Belgian Thoracic Society. 
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in Malmö, Sweden (1997). 6 Th is registry is web-based 
and includes, on November 2014, 18 countries and 5147 
patients. 
 In 1999, Belgium joined AIR, which resulted in 
2001, in a ﬁ rst Belgian working group settled by the 
Belgian Th oracic Society. Th e objectives of the group 
were to disseminate information concerning AATD, 
to promote the recommended screening for AATD, to 
promote preventive measures and to promote registra-
tion of cases. 
 Each Belgian chest physician can receive a web 
access to the Belgian AAT registry after inscription by 
the Belgian Th oracic Society. After introduction of new 
patients, the registry administrator will validate the case 
if the data have been correctly entered. Th e ﬁ rst Belgian 
patients were included in the AIR registry in 2003. 
 In December 2005, R. Stockley, chairman of AIR, was 
invited for participating to the Annual Meeting of the 
Belgian Th oracic Society. His presentation of the topic 
“COPD interventions: lessons from AATD” gave an 
important impulse to the activities of the Belgian Work-
ing Party. In September 2005, 18 patients were included 
in the Belgian registry and, in March 2006, 27 Belgian 
patients were included (50% new cases in 6 months). 
Nevertheless, only 0.93% of the 2,627 expected severe 
deﬁ cient patients were registered. 
 Currently, 55 patients are included in the Belgian 
registry, 36 males and 19 females. Of them 46 pheno-
typed patients are also included in AIR. Th ere were only 
9 non-smokers but 36 had stopped smoking. Nearly all 
patients tested for AAT were suﬀ ering from lung dis-
ease. Six patients were diagnosed in a context of fam-
ily screening. In no patient ﬁ rst analysis was done for a 
hepatic disease but 2 had a history of neonatal hepatitis. 
Eighteen patients were lung transplanted, 1 liver trans-
planted. Sixteen patients had, on registration, beneﬁ ted 
from augmentation therapy, and 5 from long-term 
oxygenotherapy. Between 1.6 and 2.1% of the estimated 
cases are currently registered. 
 Belgian participation to the pediatric 
Alpha1-International Registry (AIR) 
 Th irty-one severe Pi*ZZ AAT deﬁ cient patients are fol-
lowed in Brussels in “Cliniques Universitaires St Luc” 
by the Gastroenterology and Hepatology Pediatric Ser-
vice. 7 Since 2014, most of these patients were included 
in the Alpha one International Registry (AIR). 
 Position paper of the Belgian Thoracic 
Society 
 In December 2009, during the annual meeting of the Bel-
gian Th oracic Society, Belgian Guidelines for Diagnosis 
and Management of Patients with alpha1-Antitrypsin 
Deﬁ ciency were presented and published on the oﬃ  cial 
site of the Society. 8
 Th e recommendations were summarized as follows:
1.  Screening for alpha1-Antitrypsin (AAT) deﬁ ciency 
should be systematically performed on patients with 
emphysema (regardless of smoking history), COPD, 
bronchiectasis without evident aetiology, asthma with 
persistent obstruction despite treatment, liver disease 
without evident aetiology, oﬀ spring or pa rents of an 
individual with an AAT deﬁ ciency (ﬁ rst degree collat-
erals), absence of an AAT peak on electrophoresis, and 
unexplained panniculitis or anti-proteinase3 vasculitis. 
2.  Th e result of a normal or abnormal AAT serum level 
should be saved in the appropriate section of the 
patient's record to avoid needless retesting. 
3.  Looking at the AAT serum level, we can decide that 
the classical threshold above which a patient will not 
be sick or even carrier of a Z allele is above 150 mg/dL. 
Looking at the patients from the Spanish and Italian 
registries, Costa et al 9 and Gorrini et al 10 tried to clarify 
the level of normality above which they did not have to 
request complementary blood analyses for detecting 
deﬁ cient individuals or carriers. Th ey proposed simi-
lar threshold values, 114 and 113 mg/dL, respectively. 
Th ey only recommended phenotyping or genotyping 
patients whose serum levels were under these thresh-
olds. We can adopt this strategy which permits, at a 
lower cost, to detect eﬃ  ciently patients suﬀ ering of 
severe AAT deﬁ ciency and carriers. 
4. Patients with an AAT serum level <114 mg/dL, should 
undergo a pheno- and/or genotyping by sending appro-
priate samples to one of the reference labs in  Belgium 
or by sampling three large blood droplets (0,5 mL of 
blood in total) on a special card (dried blot spots). 
5.  Cards can be obtained at no cost from the secretariat 
of the Belgian Society of Pneumology. 
6.  Cards to be sent by post to the Belgian Th oracic 
Society secretariat, after ﬁ lling in clinical and 
administrative data. Th ey will be forwarded to one 
European reference laboratory (Marburg, Germany) 
for pheno- and genotyping. 
7.  Th e Marburg Laboratory will communicate the 
result to the physician. 
8.  In return, physicians are requested to register their 
patients with severe AAT deﬁ ciency (serum level 
< 50 mg/dL, Pi*Null-Null, Pi*Z-Null, Pi* ZZ, Pi*SZ, 
Pi*S-Null), once the phenotype is known, via the 
web site ( http://www.air-registry.org/be/ ). 
9.  Patients with severe AAT deﬁ ciency should be 
informed about the natural history of the disease and 
the importance of stopping smoking. Management 
of severe AAT deﬁ ciency should focus on COPD 
treatment according to guidelines, aggressive treat-
ment of pulmonary infections, vaccinations against 
inﬂ uenza, hepatitis A and hepatitis B, annual follow-
up of pulmonary function and imaging, liver tests, 
α-fetoprotein, liver echography. Augmentation ther-
apy should be considered in non-or ex-smokers with 
AAT serum level under 50 mg/dL (11 μmol/L) and 
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with moderate to severe obstruction (FEV 1 between 
30–65% predicted) or with a rapid decline in FEV 1 . 
10.  Genetic testing should be performed in all ﬁ rst 
degree relatives of a homozygous or heterozygous 
AAT deﬁ cient patient (Z or Null allele carrier). 
Genetic counselling could be provided. 
 AAT Augmentation Therapy in Belgium 
 Th e substitution therapy with puriﬁ ed AAT obtained 
from human serum has been approved by the US Food 
and Drug Administration (FDA) in 1987. It remains the 
only applicable speciﬁ c therapy for the disease but con-
troversy remains concerning eﬃ  cacy. 
 Augmentation infusions increase circulating trough 
levels of AAT to levels approximating those seen in het-
erozygous. A protective level of active AAT is restored 
in the epithelial lining ﬂ uid. 
 Augmentation therapy was available and almost com-
pletely reimbursed in Belgium until mid-2010 and 26 
patients were treated. Th ereafter the National Institute 
for Disease and Invalidity Insurance decided to continue 
to reimburse the treatment only for those patients who 
were already receiving it. No additional patient could 
be reimbursed for AAT substitution. 11 Th erefore, since 
2010, augmentation therapy is no longer reimbursed in 
Belgium for new patients. 
 Th e Belgian Th oracic Society's workgroup has been 
recently requested to express an opinion on the selection 
of patients who could beneﬁ t from the augmentation 
therapy. A discussion is ongoing for deﬁ ning eventual 
new conditions of reimbursement by the social security. 
 To eﬀ ectively limit the costs of treatment, recent stud-
ies aimed at targeting better the patients particularly 
at risk and the most susceptible to beneﬁ t from AAT 
substitution. Stockley et al. 12 suggested the importance 
of a personalized approach considering the severity of 
the lung disease, the rate of decline in lung function, age 
and frequency of exacerbations. 
 At the moment, we propose to consider substitution 
therapy in non-smokers or ex-smokers suﬀ ering from 
a severe AAT deﬁ ciency with a plasma level <50  mg/
mL, with a FEV 1 in the range of 30–60% predicted and a 
FEV 1 decline of at least 0.5% predicted per year. 
 For estimating the decline of functional parameters, a 
longitudinal analysis for at least 2–3 years is required. Th e 
measures of lung physiology must be done at least 6 weeks 
after any exacerbation and when smoking has ceased. 
 Patients with an FEV 1 in range of 60–80% predicted 
would be followed up unless they demonstrate a partic-
ularly rapid decline of FEV 1 in excess of 1.0% predicted 
per year. 
 No recommendation has been published concerning 
the interpretation of lack of eﬃ  cacy and treatment with-
drawal criteria. It is evident that a longitudinal follow-up 
of at least 3 years would be necessary while on therapy 
to determine the subsequent FEV 1 decline. Continued 
decline at the pretreatment level or an increase in the 
rate of decline would require reassessment of augmenta-
tion strategy. 
 We analyzed in 2012 the patients actually beneﬁ t-
ing from augmentation therapy. We have collected the 
functional data and the follow-up values by questioning 
the treating chest physicians individually. We included 
26 substituted patients and we were able to obtain the 
initial parameters of 24 of them. 
 Looking at the FEV 1 measured in 24 patients before 
initiating augmentation therapy (see Figure  1 ), 19 were 
 Figure 1. FEV 1 measured before augmentation therapy. 
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already in the limits suggested by the studies concern-
ing eﬃ  cacy of substitution therapy and the ATS/ERS 
re commendations. 
 Lung and liver transplantation in Belgium 
 In 2010, Van Raemdonck and Verleden 13 discussed the 
indications and the results of lung transplantation for 
respiratory failure. Belgium is amongst the world leading 
countries in terms of lung donors and lung transplants 
per inhabitants. To date, the Belgian Lung Transplan-
tation Registry accounts 821 transplants. Th irty-two 
patients are alphas (3.9%). 
 Th e “Cliniques Universitaires St Luc/Service de Gas-
troentérologie et Hépatologie pédiatrique” is a tertiary 
referral pediatric liver transplantation (LT) center under 
the supervision of Pr Etienne Sokal. In their center, they 
follow a cohort of 37 PiZZ AAT deﬁ ciency patients. 7
In the cohort (from 1974 to 2014), male predominance 
was observed (24 males and 13 females). At the time of 
AATD diagnosis, 23 of 37 (62%) PiZZ patients had neo-
natal cholestasis and/or cirrhosis. Of course, the AATD 
phenotype distribution is biased as they are a referral 
LT center. Neonatal cholestasis was the initial presenta-
tion in 18 of 23 (11 males and 7 females) while cirrhosis 
was the initial presentation in 5 males. Th irteen (56%) 
of these 23 patients developed end-stage liver disease 
requiring LT, 11 of these 13 (85%) were males, account-
ing for 46% of all male patients and 2 were PiZZ females 
(15% of all female patients). Of 24 who did not require 
LT, 10 (42%) had presented with neonatal cholestasis 
(5 males and 5 females) and 14 had no history of severe 
liver disease and diagnosis was an incidental ﬁ nding. 
Th ese results suggest a more severe evolution of liver 
disease in male children. All these patients did not have 
pulmonary symptoms at last follow-up. 
 Belgian patients group 
 Th e number of alpha patients in Belgium remained for 
a long time too small to permit the creation of a struc-
ture allowing an easy communication between Alphas. 
Having three national languages (French, Flemish and 
German) also does not help for simplifying a kind of 
exchange platform. 
 In 2012, when it was known that augmentation 
therapy would not be further reimbursed by the Pub-
lic Health System for newly diagnosed Alphas, several 
Belgian patients met for trying to ﬁ nd solutions. As in 
other countries where alpha patients’ organizations are 
established, they decided to found a group and named 
it Alpha-1 Belgium. Th e association remained with no 
legal base or structure or subsides, but in contact with 
patients and medical doctors. Th e most important goals 
were to create awareness about the disease and to con-
tact the Public Health Structures. 
 In 2013, the group was represented at the 4 th interna-
tional Alpha-1 congress for patients hold in Barcelona 
and met other patient organizations but also attended 
the scientiﬁ c program and conferences. 
 Another event in summer 2013 was the meeting with 
two members of the European Parliament to create aware-
ness about the Belgian lack of reimbursement. Th e Belgian 
Minister of Public Health was contacted a month later. 
 In autumn 2013 the necessity for a stand-alone, legal 
and registered structure led the patient group to create a 
new not-for-proﬁ t association called Alpha-1 Plus asbl/
vzw. Th e missions and goals were to:  
 Provide support and information for Alpha patients; 
 Promote education and awareness of the disease; 
 Advocate for Alpha patients and community; 
 Communicate with other health-related structures in 
diﬀ erent countries.
 Basic orientation about the disease is available in French, 
Flemish, English and German. 
 Unlike other countries there are no speciﬁ c clinical 
reference centers for Alpha-1 in Belgium yet. Most of 
the members of the Alpha-1 Plus association were diag-
nosed before June 2010, so they are therefore still being 
augmented. Several meetings of a round table discussion, 
moderated by a professional therapist, allow the members 
to communicate with other patients about treatment and 
personal experiences. 
 Alpha-1 Plus asbl/vzw is also a member of:
 Th e European Alpha-1 Federation; 
 Radiorg (rare diseases in Belgium); 
 Eurodis (European rare disease organization); 
 EFA (European Federation of Allergy and Airway dis-
eases Patient Associations). 
 Th ere are contacts with patient organizations in other 
countries (Germany, France, Denmark). 
 Finally, in June 2014, the Belgian association assisted 
to create another new structure called Alpha-1 Global, 
a group of 7 volunteers who are patient representatives 
of Alpha patient groups. Th e mission of Alpha-1 Global 
is to create a collaborative network of Alpha-1 organiza-
tions and patients to increase awareness, detection and 
access to care for Alphas around the world. Th e ﬁ rst tool 
is to create an Internet platform for patients, medical 
and care professionals and researchers to communicate 
about the disease. 
 Conclusions 
 Th e Belgian activities concerning AAT deﬁ ciency are 
growing. Th e screening and registration remain insuf-
ﬁ cient as it is also the case in nearly all other countries. 
 Nevertheless we can say that since 1999 and our par-
ticipation in AIR we have put Belgium on the map. We 
will continue to boost the integrated activities of all the 
stakeholders involved in AAT deﬁ ciency, with the ulti-
mate goal to appropriately screen advice and eventually 
treat all AAT patients suﬀ ering from this disabling disease. 
 Also, feedback from patients and communication 
with patients’ organizations stimulate awareness and 
knowledge of this rare disease. 
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